Literature DB >> 20184396

ADAM-17: the enzyme that does it all.

Monika Gooz1.   

Abstract

This review focuses on the role of ADAM-17 in disease. Since its debut as the tumor necrosis factor converting enzyme (TACE), ADAM-17 has been reported to be an indispensible regulator of almost every cellular event from proliferation to migration. The central role of ADAM-17 in cell regulation is rooted in its diverse array of substrates: cytokines, growth factors, and their receptors as well as adhesion molecules are activated or inactivated by their cleavage with ADAM-17. It is therefore not surprising that ADAM-17 is implicated in numerous human diseases including cancer, heart disease, diabetes, rheumatoid arthritis, kidney fibrosis, Alzheimer's disease, and is a promising target for future treatments. The specific role of ADAM-17 in the pathophysiology of these diseases is very complex and depends on the cellular context. To exploit the therapeutic potential of ADAM-17, it is important to understand how its activity is regulated and how specific organs and cells can be targeted to inactivate or activate the enzyme.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184396      PMCID: PMC2841225          DOI: 10.3109/10409231003628015

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  292 in total

Review 1.  Current perspective of TACE inhibitors: a review.

Authors:  Shirshendu DasGupta; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Bioorg Med Chem       Date:  2008-12-03       Impact factor: 3.641

2.  Deficiency of TNFalpha converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice.

Authors:  Richard W Gelling; Wenbo Yan; Salwa Al-Noori; Aaron Pardini; Gregory J Morton; Kayoko Ogimoto; Michael W Schwartz; Peter J Dempsey
Journal:  Endocrinology       Date:  2008-08-07       Impact factor: 4.736

3.  DLG1/SAP97 modulates transforming growth factor alpha bioavailability.

Authors:  Anne-Laure Surena; Giselle P de Faria; Jeanne-Marie Studler; Franck Peiretti; Morgane Pidoux; Jacques Camonis; Hervé Chneiweiss; Etienne Formstecher; Marie-Pierre Junier
Journal:  Biochim Biophys Acta       Date:  2008-09-27

4.  Neuronal RA175/SynCAM1 isoforms are processed by tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM17-like proteases.

Authors:  Yuko Tanabe; Tadashi Kasahara; Takashi Momoi; Eriko Fujita
Journal:  Neurosci Lett       Date:  2008-08-13       Impact factor: 3.046

5.  ERK1/2 mediate wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding.

Authors:  Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-24       Impact factor: 4.799

6.  Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.

Authors:  Aramati B M Reddy; Kota V Ramana; Sanjay Srivastava; Aruni Bhatnagar; Satish K Srivastava
Journal:  Endocrinology       Date:  2008-09-04       Impact factor: 4.736

7.  Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice.

Authors:  Rossella Menghini; Stefano Menini; Roberta Amoruso; Loredana Fiorentino; Viviana Casagrande; Valeria Marzano; Federica Tornei; Pierfrancesco Bertucci; Carla Iacobini; Matteo Serino; Ottavia Porzio; Marta L Hribal; Franco Folli; Rama Khokha; Andrea Urbani; Renato Lauro; Giuseppe Pugliese; Massimo Federici
Journal:  Gastroenterology       Date:  2008-11-06       Impact factor: 22.682

8.  Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.

Authors:  Minkyu L Kim; Bin Zhang; Ian P Mills; Marcos E Milla; Kurt R Brunden; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

9.  VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.

Authors:  Steven Swendeman; Karen Mendelson; Gisela Weskamp; Keisuke Horiuchi; Urban Deutsch; Peggy Scherle; Andrea Hooper; Shahin Rafii; Carl P Blobel
Journal:  Circ Res       Date:  2008-09-25       Impact factor: 17.367

Review 10.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
View more
  163 in total

1.  Lentivirus-mediated ADAM17 RNA interference inhibited interleukin-8 expression via EGFR signaling in lung epithelial cells.

Authors:  Yaqing Li; Jianping Yan; Wulin Xu; Hong Wang; Yingjie Xia
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Salt-Mediated Nanopore Detection of ADAM-17.

Authors:  Xiaohan Chen; Youwen Zhang; Golbarg Mohammadi Roozbahani; Xiyun Guan
Journal:  ACS Appl Bio Mater       Date:  2018-12-24

3.  Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α-converting enzyme.

Authors:  Justin B Schaal; Thorsten Maretzky; Dat Q Tran; Patti A Tran; Prasad Tongaonkar; Carl P Blobel; André J Ouellette; Michael E Selsted
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

4.  High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.

Authors:  Lidan Wu; Allison M Claas; Aniruddh Sarkar; Douglas A Lauffenburger; Jongyoon Han
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

5.  PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

Authors:  Mathéa Pietri; Caroline Dakowski; Samia Hannaoui; Aurélie Alleaume-Butaux; Julia Hernandez-Rapp; Audrey Ragagnin; Sophie Mouillet-Richard; Stéphane Haik; Yannick Bailly; Jean-Michel Peyrin; Jean-Marie Launay; Odile Kellermann; Benoit Schneider
Journal:  Nat Med       Date:  2013-08-18       Impact factor: 53.440

6.  Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction.

Authors:  Huijuan Dou; Attila Feher; Alec C Davila; Maritza J Romero; Vijay S Patel; Vinayak M Kamath; Monika Beck Gooz; R Daniel Rudic; Rudolf Lucas; David J Fulton; Neal L Weintraub; Zsolt Bagi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

Review 7.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

8.  A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.

Authors:  Dan-Dan Li; Chang-Hao Zhao; Huai-Wei Ding; Qiong Wu; Tian-Shu Ren; Jian Wang; Cong-Qin Chen; Qing-Chun Zhao
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

Review 9.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

10.  Modulation of CD163 expression by metalloprotease ADAM17 regulates porcine reproductive and respiratory syndrome virus entry.

Authors:  Longjun Guo; Junwei Niu; Haidong Yu; Weihong Gu; Ren Li; Xiaolei Luo; Mingming Huang; Zhijun Tian; Li Feng; Yue Wang
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.